FDAapproval65% confidence
FDA approves capivasertib with abiraterone and prednisone for PTEN-deficient androgen pathway modulation-naïve or -sensitive prostate cancer
Source: FDA
Why This Matters
Why this matters: provides agency context on approval that may shape timing or evidence expectations for MD Anderson.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Oncology · Oropharyngeal Cancer
- Sub-indication
- General
Related signal: MRI-Guided Radiotherapy Trial for HPV Positive Oropharyngeal Cancer Initiated